Raves and risks for erythropoietin.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cytokine & growth factor reviews

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cytogfr.2008.01.004PMID 18299246PMCID PMC2388244
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The impact of tumor expression of erythropoietin receptors and erythropoietin on clinical outcome of esophageal cancer patients treated with chemoradiation.

  2008cited by this paper
• Erythropoietin involves the phosphatidylinositol 3‐kinase pathway, 14‐3‐3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity

  2007cited by this paper
• Erythropoietin Protects from Post-Traumatic Edema in the Rat Brain

  2007cited by this paper
• Effects of a Single Dose of Erythropoietin on Subsequent Seizure Susceptibility in Rats Exposed to Acute Hypoxia at P10

  2007cited by this paper
• Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt/GSK-3β/caspase-3 mediated signaling pathway

  2007cited by this paper
• Brain Erythropoietin Receptor Expression in Alzheimer Disease and Mild Cognitive Impairment

  2007cited by this paper
• Erythropoietin modulation of podocalyxin and a proposed erythroblast niche.

  2007cited by this paper
• Erythropoietin: A Candidate Neuroprotective Agent in the Treatment of Glaucoma

  2007cited by this paper
• Erythropoietin Induces Excessive Neointima Formation: A Study in a Rat Carotid Artery Model of Vascular Injury

  2007cited by this paper
• Erythropoietin Reduces Ischemia-Reperfusion Injury in the Rat Liver

  2007cited by this paper
• Expression of Erythropoietin Receptor and In vitro Functional Effects of Epoetins in B-Cell Malignancies

  2007cited by this paper
• A genetic association analysis of cognitive ability and cognitive ageing using 325 markers for 109 genes associated with oxidative stress or cognition

  2007cited by this paper
• Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction.

  2007cited by this paper
• Efficacy and safety of epoetin alfa in critically ill patients.

  2007cited by this paper
• Neuroprotection with Erythropoietin Administration Following Controlled Cortical Impact Injury in Rats

  2007cited by this paper
• Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression.

  2007cited by this paper
• Oxygen Sensing : Life and Death of a Cell Hypoxic preconditioning protects human brain endothelium from ischemic apoptosis by Akt-dependent survivin activation

  2007cited by this paper
• Protective Role of Endogenous Erythropoietin System in Nonhematopoietic Cells Against Pressure Overload-Induced Left Ventricular Dysfunction in Mice

  2007cited by this paper
• Neuronal Apoptosis in Neurodegeneration

  2007cited by this paper
• An extracellular region of the erythropoietin receptor of the subterranean blind mole rat Spalax enhances receptor maturation

  2007cited by this paper
• Erythropoietin-Induced Neurovascular Protection, Angiogenesis, and Cerebral Blood Flow Restoration after Focal Ischemia in Mice

  2007influential reference
• GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder.

  2007cited by this paper
• Wnts: up-and-coming at the synapse.

  2007cited by this paper
• Regulation of FOXO3a/β-Catenin/GSK-3β Signaling by 3,3′-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Prostate Cancer Cells*

  2007cited by this paper
• Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization.

  2007cited by this paper
• Recombinant human erythropoietin α modulates the effects of radiotherapy on colorectal cancer microvessels

  2007cited by this paper
• Erythropoietin Enhances Long-Term Neuroprotection and Neurogenesis in Neonatal Stroke

  2007cited by this paper
• Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure

  2007cited by this paper
• Recombinant human erythropoietin decreases myeloperoxidase and caspase-3 activity and improves early functional results after spinal cord injury in rats.

  2007cited by this paper
• Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.

  2007cited by this paper
• Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat

  2007cited by this paper
• Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart.

  2007cited by this paper
• Erythropoietin and treatment of non-anemic conditions--cardiovascular protection.

  2007influential reference
• Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion.

  2007cited by this paper
• Mechanistic insights into diabetes mellitus and oxidative stress.

  2007cited by this paper
• Human recombinant erythropoietin protects the striated muscle microcirculation of the dorsal skinfold from postischemic injury in mice.

  2007cited by this paper
• Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus.

  2007cited by this paper
• The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection.

  2007cited by this paper
• The role of erythropoietin in central and peripheral nerve injury.

  2007cited by this paper
• "Sly as a FOXO": new paths with Forkhead signaling in the brain.

  2007cited by this paper
• The Effect of Recombinant Human Erythropoietin on Neurovasculature Repair after Focal Ischemic Stroke in Neonatal Rats

  2007cited by this paper
• Reduced Cerebral Blood Flow but Elevated Cerebral Glucose Metabolic Rate in Erythropoietin Overexpressing Transgenic Mice with Excessive Erythrocytosis

  2007cited by this paper
• Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling.

  2007cited by this paper
• Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus.

  2007cited by this paper
• Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways.

  2007cited by this paper
• Treatment of severe scleroderma skin ulcers with recombinant human erythropoietin

  2007cited by this paper
• Adrenomedullin in the kidney-renal physiological and pathophysiological roles.

  2007cited by this paper
• Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.

  2006influential reference
• The interaction between heart failure and other heart diseases, renal failure, and anemia.

  2006influential reference
• Angiogenesis and endothelial cell repair in renal disease and allograft rejection.

  2006cited by this paper
• A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span.

  2006cited by this paper
• Erythropoietin Concentrations and Neurodevelopmental Outcome in Preterm Infants

  2006cited by this paper
• High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction

  2006cited by this paper
• In vivo evaluation of EPO-secreting cells immobilized in different alginate-PLL microcapsules.

  2006cited by this paper
• Erythropoietin and GDNF enhance ventral mesencephalic fiber outgrowth and capillary proliferation following neural transplantation in a rodent model of Parkinson's disease

  2006cited by this paper
• Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and beta-catenin during oxidative stress.

  2006cited by this paper
• Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model.

  2006cited by this paper
• Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure.

  2006cited by this paper
• Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats.

  2006cited by this paper
• Cell Life versus cell longevity: the mysteries surrounding the NAD+ precursor nicotinamide.

  2006cited by this paper
• Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB.

  2006cited by this paper
• Proteomics and heart disease: identifying biomarkers of clinical utility

  2006cited by this paper
• Microglial Integrity is Maintained by Erythropoietin Through Integration of Akt and Its Substrates of Glycogen Synthase Kinase-3β, β-Catenin, and Nuclear Factor-κB

  2006cited by this paper
• Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity.

  2005cited by this paper
• Erythropoietin Requires NF-κB and its Nuclear Translocation to Prevent Early and Late Apoptotic Neuronal Injury During β-Amyloid Toxicity

  2005cited by this paper
• New avenues of exploration for erythropoietin.

  2005cited by this paper
• mGluRI targets microglial activation and selectively prevents neuronal cell engulfment through Akt and caspase dependent pathways.

  2005cited by this paper
• Erythropoietin and cancer.

  2005cited by this paper
• Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia.

  2005cited by this paper
• Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease.

  2005cited by this paper
• Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules.

  2005cited by this paper
• Erythropoietin and Cancer—Reply

  2005cited by this paper
• Erythropoietin Abuse and Erythropoietin Gene Doping

  2005cited by this paper
• AKT1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-xL and caspase 1, 3, and 9.

  2004cited by this paper
• The NAD+ Precursor Nicotinamide Governs Neuronal Survival During Oxidative Stress Through Protein Kinase B Coupled to FOXO3a and Mitochondrial Membrane Potential

  2004cited by this paper
• Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model.

  2004cited by this paper
• High amniotic fluid erythropoietin levels are associated with an increased frequency of fetal and neonatal morbidity in Type 1 diabetic pregnancies

  2004cited by this paper
• Erythropoietin in the brain: can the promise to protect be fulfilled?

  2004cited by this paper
• Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity

  2003cited by this paper
• Apaf-1, Bcl-xL, Cytochrome c, and Caspase-9 Form the Critical Elements for Cerebral Vascular Protection by Erythropoietin

  2003cited by this paper
• Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8

  2003cited by this paper
• Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase‐mediated pathways

  2003cited by this paper
• Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation.

  2003cited by this paper
• Erythropoietin Is a Novel Vascular Protectant Through Activation of Akt1 and Mitochondrial Modulation of Cysteine Proteases

  2002cited by this paper
• [Erythropoietin and cancer].

  1992cited by this paper
• Van Damme A.

  1986cited by this paper

• Induction of Erythropoietin by dietary Medium-Chain Triacylglycerol in Humans.

  2025cites this paper
• Dietary medium-chain triacylglycerols in metabolic regulation.

  2025cites this paper
• Innovative therapeutic strategies for cardiovascular disease

  2023influential citation
• Cellular Metabolism: A Fundamental Component of Degeneration in the Nervous System

  2023cites this paper
• Ferroptosis, Iron Metabolism, and Forkhead Transcription Factors (FoxOs).

  2023cites this paper
• The cytokine receptor CRLF3 is a human neuroprotective EV-3 (Epo) receptor

  2023cites this paper
• Cognitive Impairment and Dementia: Gaining Insight through Circadian Clock Gene Pathways

  2021cites this paper
• Neurodegeneration, memory loss, and dementia: the impact of biological clocks and circadian rhythm

  2021cites this paper
• Sirtuins in metabolic disease: innovative therapeutic strategies with SIRT1, AMPK, mTOR, and nicotinamide

  2021cites this paper
• Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders.

  2021cites this paper
• Role of Mesenchymal Stem Cell in Identification of Hemotoxic Effect of sFas in cases of Nephrotoxicity

  2020cites this paper
• Nicotinamide: Oversight of Metabolic Dysfunction through SIRT1, mTOR, and Clock Genes.

  2020cites this paper
• New Insights for nicotinamide: Metabolic disease, autophagy, and mTOR.

  2020cites this paper
• Cognitive impairment with diabetes mellitus and metabolic disease: innovative insights with the mechanistic target of rapamycin and circadian clock gene pathways

  2019cites this paper
• Multiple spectroscopic studies of the interaction between a quaternary ammonium-based cationic Gemini surfactant (as a carrier) and human erythropoietin

  2018cites this paper
• Erythropoietin: A potential drug in the management of diabetic neuropathy.

  2018cites this paper
• Novel Pathways of Autophagy for the Treatment of Nervous System Disorders

  2018cites this paper
• The Influence of Erythropoietin (EPO) on Cancer Cells and its Role in the Cancer Treatment

  2017influential citation
• Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin.

  2017cites this paper
• Administration of erythropoietin prevents bone loss in osteonecrosis of the femoral head in mice

  2017cites this paper
• Regeneration in the nervous system with erythropoietin.

  2016cites this paper
• Regeneration in the nervous system with erythropoietin.

  2016cites this paper
• Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR

  2016cites this paper
• Resveratrol Ameliorates the Components of Hepatic Inflammation and Apoptosis in a Rat Model of Streptozotocin‐Induced Diabetes

  2016cites this paper
• Avaliação da resposta à eritropoetina no tratamento de pacientes portadores de síndrome mielodisplásica

  2016cites this paper
• Novel Stem Cell Strategies with mTOR

  2016cites this paper
• Epo pretreatment of Ecfcs enhances functional recovery after transplantation in a rat model of cerebral ischemia through an increase of their homing abilities: a Spect/ct study: Co-078

  2016cites this paper
• Erythropoietin Pretreatment of Transplanted Endothelial Colony-Forming Cells Enhances Recovery in a Cerebral Ischemia Model by Increasing Their Homing Ability: A SPECT/CT Study

  2016cites this paper
• Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy.

  2016cites this paper
• Erythropoiesis in Health and Disease – Erythropoietin ’ s In Charge !

  2015cites this paper
• FoxO Proteins in the Nervous System

  2015cites this paper
• Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease

  2015influential citation
• New Insights for Oxidative Stress and Diabetes Mellitus

  2015cites this paper
• Erythropoietin and diabetes mellitus.

  2015cites this paper
• FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus.

  2015cites this paper
• The application of a new method in the treatment of Alzheimer's disease induced by streptozotocin in male Wistar rats with reduced hematocrit effects

  2015cites this paper
• Synergistic neroprotective activiity of benfotiamine co administered with erythropoietin in chemotherapy induced peripheral neuropathy in rats

  2015cites this paper
• Dual Delivery of EPO and BMP2 from a Novel Modular Poly-ɛ-Caprolactone Construct to Increase the Bone Formation in Prefabricated Bone Flaps

  2015cites this paper
• Side Effects of Cytokines Approved for Therapy

  2014cites this paper
• Erythropoietin Reduces Acute Lung Injury and Multiple Organ Failure/Dysfunction Associated to a Scald-Burn Inflammatory Injury in the Rat

  2014cites this paper
• Cutting through the complexities of mTOR for the treatment of stroke.

  2014cites this paper
• Assessment of recombinant human erythropoietin by alternative bioassay and its correlation with liquid chromatography methods

  2013cites this paper
• Translation of the human erythropoietin transcript is regulated by an upstream open reading frame in response to hypoxia

  2013cites this paper
• Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy.

  2013cites this paper
• ERITROPOETINA: SÍNTESE E LIBERAÇÃO FISIOLÓGICA E O USO DE SUA FORMA RECOMBINANTE NO ESPORTE

  2013cites this paper
• Rapid Generation of Stable Cell Lines Expressing High Levels of Erythropoietin, Factor VIII, and an Antihuman CD20 Antibody Using Lentiviral Vectors

  2013cites this paper
• The use of darbepoetin to stimulate erythropoiesis in anemia of chronic kidney disease in cats: 25 cases.

  2012cites this paper
• PRAS40 Is an Integral Regulatory Component of Erythropoietin mTOR Signaling and Cytoprotection

  2012cites this paper
• SIRT1: new avenues of discovery for disorders of oxidative stress

  2012cites this paper
• Management of Anemia of Inflammation in the Elderly

  2012cites this paper
• Treating patients with schizophrenia deficit with erythropoietin?

  2012cites this paper
• Erythropoietin: New Directions for the Nervous System

  2012influential citation
• Targeting cardiovascular disease with novel SIRT1 pathways.

  2012cites this paper
• A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.

  2012cites this paper
• Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL

  2012cites this paper
• Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xL.

  2012cites this paper
• Plasminogen deficiency attenuates postnatal erythropoiesis in male C57BL/6 mice through decreased activity of the LH-testosterone axis.

  2012cites this paper
• Post-cardiac arrest brain injury: pathophysiology and treatment.

  2012cites this paper
• Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.

  2012cites this paper
• Can local Erythropoietin administration enhance bone regeneration in osteonecrosis of femoral head?

  2012cites this paper
• Short-term intra-nasal erythropoietin administration with low sialic acid content is without toxicity or erythropoietic effects.

  2012cites this paper
• MT1-MMP plays a critical role in hematopoiesis by regulating HIF-mediated chemokine/cytokine gene transcription within niche cells.

  2012cites this paper
• EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β, and β-catenin to foster vascular integrity during experimental diabetes.

  2011cites this paper
• Absence of hematological side effects in acute and subacute nasal dosing of erythropoietin with a low content of sialic acid.

  2011cites this paper
• The potential role of erythropoietin as a pleiotropic agent in post-cardiac arrest syndrome.

  2011cites this paper
• Novel Avenues of Drug Discovery and Biomarkers for Diabetes Mellitus

  2011cites this paper
• Translating cell survival and cell longevity into treatment strategies with SIRT1.

  2011cites this paper
• EPO (Erythropoietin) - Drug utilisation research im Krankenhaus der Barmherzigen Brüder Eisenstadt

  2011cites this paper
• Neuroprotective cytokines repress PUMA induction in the 1-methyl-4-phenylpyridinium (MPP(+)) model of Parkinson's disease.

  2011cites this paper
• Erythropoietin Levels Are Not Independently Associated with Malaria-Attributable Severe Disease in Mozambican Children

  2011cites this paper
• Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia.

  2011cites this paper
• Anemia of Renal Disease

  2011cites this paper
• Glucocorticoid Protection of Oligodendrocytes against Excitotoxin Involving Hypoxia-Inducible Factor-1α in a Cell-Type-Specific Manner

  2010cites this paper
• Prevention of acute kidney injury and protection of renal function in the intensive care unit

  2010cites this paper
• Novel Strategies for Neurovascular Longevity During Aging

  2010cites this paper
• Mammalian Target of Rapamycin: Hitting the Bull's-Eye for Neurological Disorders

  2010cites this paper
• Erythropoietin for the treatment of subarachnoid hemorrhage: a review.

  2010cites this paper
• Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation.

  2010cites this paper
• Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways.

  2010influential citation
• Erythropoetin as a novel agent with pleiotropic effects against acute lung injury

  2010influential citation
• Non-erythropoietic tissue-protective peptides derived from erythropoietin: WO2009094172

  2010cites this paper
• Patent Evaluation Non-erythropoietic tissue-protective peptides derived from erythropoietin : WO 2009094172

  2010cites this paper
• Diabetes mellitus: channeling care through cellular discovery.

  2010cites this paper
• Oxidative stress: Biomarkers and novel therapeutic pathways

  2010influential citation
• For Peer Review MODIFICATION OF GENE EXPRESSION: HELP TO DETECT DOPING WITH ERYTHROPOIESIS-STIMULATING AGENTS

  2009cites this paper
• Monocytes from patients with myelodysplastic syndromes are more resistant to inhibition by thalidomide

  2009cites this paper
• New strategies for Alzheimer disease and cognitive impairment

  2009cites this paper
• The "O" class: crafting clinical care with FoxO transcription factors.

  2009cites this paper
• The Vitamin Nicotinamide: Translating Nutrition into Clinical Care

  2009cites this paper
• Uncertainty and discordance in the staging and prognosis of diffuse large B‐cell lymphoma with isolated bilateral testicular involvement

  2009cites this paper
• FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis.

  2009influential citation
• Erythropoietin, Forkhead Proteins, and Oxidative Injury: Biomarkers and Biology

  2009influential citation
• Treatment with hydroxyurea in a patient compound heterozygote for a high oxygen affinity hemoglobin and β‐thalassemia minor

  2009cites this paper
• FoxO proteins: cunning concepts and considerations for the cardiovascular system.

  2009cites this paper
• Possible graft‐versus‐host disease involving the central nervous system soon after cord blood transplantation

  2009cites this paper
• A fork in the path

  2009cites this paper
• A “FOXO” in sight: Targeting Foxo proteins from conception to cancer

  2009cites this paper
• Enhanced tolerance against early and late apoptotic oxidative stress in mammalian neurons through nicotinamidase and sirtuin mediated pathways.

  2008cites this paper
• Rogue proliferation versus restorative protection: Where do we draw the line for Wnt and Forkhead signaling?

  2008cites this paper
• Therapeutic promise and principles

  2008cites this paper